CN117794538A - 用于治疗α1-抗胰蛋白酶缺乏症的组合物及其用途 - Google Patents

用于治疗α1-抗胰蛋白酶缺乏症的组合物及其用途 Download PDF

Info

Publication number
CN117794538A
CN117794538A CN202280053656.2A CN202280053656A CN117794538A CN 117794538 A CN117794538 A CN 117794538A CN 202280053656 A CN202280053656 A CN 202280053656A CN 117794538 A CN117794538 A CN 117794538A
Authority
CN
China
Prior art keywords
piperidine
sulfonyl
carboxylic acid
trifluoromethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280053656.2A
Other languages
English (en)
Chinese (zh)
Inventor
尼杰尔·拉姆斯登
大卫·约翰·福克斯
詹姆斯·安德鲁·亨廷顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sentesa Pharmaceuticals Uk Ltd
Original Assignee
Sentesa Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentesa Pharmaceuticals Uk Ltd filed Critical Sentesa Pharmaceuticals Uk Ltd
Publication of CN117794538A publication Critical patent/CN117794538A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280053656.2A 2021-06-15 2022-06-15 用于治疗α1-抗胰蛋白酶缺乏症的组合物及其用途 Pending CN117794538A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency
GB2108523.8 2021-06-15
PCT/GB2022/051502 WO2022263816A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
CN117794538A true CN117794538A (zh) 2024-03-29

Family

ID=76954605

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280053656.2A Pending CN117794538A (zh) 2021-06-15 2022-06-15 用于治疗α1-抗胰蛋白酶缺乏症的组合物及其用途

Country Status (12)

Country Link
US (1) US12673050B2 (enExample)
EP (1) EP4355328A1 (enExample)
JP (1) JP7854001B2 (enExample)
KR (1) KR20240027693A (enExample)
CN (1) CN117794538A (enExample)
AU (1) AU2022295130A1 (enExample)
BR (1) BR112023026510A2 (enExample)
CA (1) CA3223130A1 (enExample)
GB (1) GB202108523D0 (enExample)
IL (1) IL309355A (enExample)
MX (1) MX2023015398A (enExample)
WO (1) WO2022263816A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
JP3391038B2 (ja) 1991-12-26 2003-03-31 富士レビオ株式会社 カルボン酸アミド誘導体
WO2005113542A2 (en) 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
WO2012097371A2 (en) * 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
CN110325527B (zh) 2016-12-09 2022-08-09 勃林格殷格翰国际有限公司 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺
CA3103920C (en) 2018-06-22 2025-09-16 Ucl Business Ltd COMPOUNDS FOR TREATING DISEASES MEDIATED BY ALPHA-1 ANTITRYPSIN
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918410D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Also Published As

Publication number Publication date
JP7854001B2 (ja) 2026-04-30
US12673050B2 (en) 2026-07-07
JP2024523406A (ja) 2024-06-28
US20240197707A1 (en) 2024-06-20
AU2022295130A1 (en) 2024-01-18
MX2023015398A (es) 2024-04-29
GB202108523D0 (en) 2021-07-28
BR112023026510A2 (pt) 2024-03-05
KR20240027693A (ko) 2024-03-04
CA3223130A1 (en) 2022-12-22
IL309355A (en) 2024-02-01
EP4355328A1 (en) 2024-04-24
WO2022263816A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
CN113227057B (zh) 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途
US12611402B2 (en) Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency
US20240197707A1 (en) Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency
CN115023416B (zh) 用于治疗α1-抗胰蛋白酶缺乏症的4-((2-氧代吡啶-1(2H)-基)甲基)苯甲酰胺
EP4073043B1 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN115003381B (zh) 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途
CN115003669B (zh) 化合物及其用于治疗α1-抗胰蛋白酶缺乏症的用途
HK40079913A (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK40079913B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination